S. Rodenhuis

发表

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Yudong D. He, M. Marton, S. Friend, 2002 .

Clinical significance of ras oncogene activation in human lung cancer.

S. Rodenhuis, R. Slebos, R. Slebos, 1992, Cancer research.

Prognostic factors in NSCLC. Recent experiences.

S. Rodenhuis, N. van Zandwijk, W. Mooi, 1995, Lung cancer.

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

S. Rodenhuis, J. Bos, N. van Zandwijk, 1987, The New England journal of medicine.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Wim H van Harten, Valesca P Retel, Guido Brink, 2007, The Lancet. Oncology.

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.

S. Rodenhuis, J. Wesseling, K. Gilhuijs, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla

S. Rodenhuis, E. Rutgers, J. Wesseling, 2013, Annals of Surgical Oncology.

Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy

S. Rodenhuis, E. Rutgers, P. Elkhuizen, 2013, Breast Cancer Research and Treatment.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

S. Rodenhuis, L. Rigter, S. Linn, 2013, British Journal of Cancer.

Clinical Pharmacokinetics of Cyclophosphamide

S. Rodenhuis, J. Beijnen, A. Huitema, 1979, Clinical pharmacokinetics.

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Cancer Chemotherapy and Pharmacology.

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes

M. Bonder, S. Rodenhuis, L. Wessels, 2014, PloS one.

University of Groningen Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes de Ronde,

M. Bonder, S. Rodenhuis, L. Wessels, 2014 .

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2003, British Journal of Cancer.

Oncogenes and human lung cancer.

S. Rodenhuis, 1989, Cancer treatment and research.

Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate.

S. Rodenhuis, J. Kremer, J. Bertino, 1987, Arthritis and rheumatism.

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.

M. J. van de Vijver, S. Rodenhuis, L. Wessels, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

S. Rodenhuis, J. Schrama, J. Schornagel, 2003, British Journal of Cancer.

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

A. Hart, S. Rodenhuis, L. J. Veer, 2003, British Journal of Cancer.

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

S. Rodenhuis, J. Schellens, J. Beijnen, 2005, British journal of clinical pharmacology.

Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction

S. Rodenhuis, J. Beijnen, A. Huitema, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

New treatment opportunities in non-small cell lung cancer

S. Rodenhuis, W. Mooi, N. Zandwijk, 1993 .

N‐ and KRAS mutations in primary testicular germ cell tumors: Incidence and possible biological implications

S. Rodenhuis, L. Looijenga, J. Oosterhuis, 1995, Genes, chromosomes & cancer.

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

The use of the Calvert formula to determine the optimal carboplatin dosage

S. Rodenhuis, J. Beijnen, R. Maes, 2005, Journal of Cancer Research and Clinical Oncology.

Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking

S. Goodman, S. Rodenhuis, R. Hruban, 1993, The American journal of surgical pathology.

Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer.

S. Rodenhuis, L. J. Veer, S. Linn, 2009 .

K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung.

S. Goodman, S. Rodenhuis, R. Hruban, 1993, Cancer.

ras and human tumors.

S. Rodenhuis, 1992, Seminars in cancer biology.

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, R. Mathôt, 2002, Cancer Chemotherapy and Pharmacology.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

S. Rodenhuis, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

S. Rodenhuis, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy

S. Rodenhuis, E. Rutgers, K. Gilhuijs, 2012 .

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2001, British journal of clinical pharmacology.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

S. Rodenhuis, H. V. van Boven, J. Schellens, 2007, Investigational New Drugs.

Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.

S. Rodenhuis, O. Dalesio, R. Hruban, 1991, Journal of the National Cancer Institute.

Association of H‐ras mutations with adenocarcinomas of the parotid gland

S. Rodenhuis, A. Balm, H. V. van Halteren, 1994, International journal of cancer.

Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

S. Rodenhuis, S. Wagenaar, R. Slebos, 1988, Cancer research.

New treatment opportunities in non-small cell lung cancer

S. Rodenhuis, W. Mooi, N. Zandwijk, 1993 .

Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer

S. Rodenhuis, W. Mooi, H. Elbers, 1995, International journal of cancer.

A Rapid and Simple Procedure for the Routine Detection of ras Point Mutations in Formalin‐Fixed, Paraffin‐Embedded Tissues

S. Rodenhuis, R. Slebos, R. Slebos, 1992, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

L. V. van't Veer, S. Rodenhuis, R. Slebos, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ras oncogenes in human lung cancer.

S. Rodenhuis, R. Slebos, R. Slebos, 1990, The American review of respiratory disease.

The ras gene family in human non-small-cell lung cancer.

S. Rodenhuis, R. Slebos, Slebos Rj, 1992, Journal of the National Cancer Institute. Monographs.

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

S. Rodenhuis, D. Weiner, R. Slebos, 1994, The Journal of clinical investigation.

Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood

S. Rodenhuis, J. Bos, L. Smets, 1986 .

The role of high-dose chemotherapy in breast cancer

S. Rodenhuis, 2006 .

Is high-dose chemotherapy dead?

S. Rodenhuis, 2005, European journal of cancer.

Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy

S. Rodenhuis, A. Huitema, M. E. Jonge, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

S. Rodenhuis, A. Huitema, M. E. Jonge, 2006, British Journal of Cancer.

Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC)

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Cancer Chemotherapy and Pharmacology.

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination

S. Rodenhuis, J. Beijnen, O. Tellingen, 2004, Cancer Chemotherapy and Pharmacology.

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2000, Anti-cancer drugs.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1992, British Journal of Cancer.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

S. Rodenhuis, J. Sein, A. Hekman, 1993, British Journal of Cancer.

Patient motivation and informed consent in a phase I study of an anticancer agent.

S. Rodenhuis, N. Mulder, D. Sleijfer, 1984, European journal of cancer & clinical oncology.

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer

S. Rodenhuis, L. Wessels, J. Wesseling, 2012, Breast Cancer Research and Treatment.

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

S. Rodenhuis, E. Rutgers, S. Linn, 2008, Nederlands tijdschrift voor geneeskunde.

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

S. Rodenhuis, C. Melief, J. Sein, 2005, Cancer Immunology, Immunotherapy.

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy

S. Rodenhuis, O. Dalesio, J. Beijnen, 2002, Bone Marrow Transplantation.

A Method to Monitor mRNA Levels in Human Breast Tumor Cells Obtained by Fine‐needle Aspiration

L. V. van't Veer, S. Rodenhuis, H. Peterse, 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

S. Rodenhuis, J. Baars, D. Richel, 1995, British Journal of Cancer.

Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia.

S. Rodenhuis, L. Smets, R. Slater, 1985, The New England journal of medicine.

A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1992 .

Reconstitution of interleukin-2

S. Rodenhuis, A. Hekman, E. Rankin, 1990, The Lancet.

Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.

S. Rodenhuis, O. Dalesio, D. Richel, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (PSCT) in Patients with Malignant Lymphomas and Solid Tumors

S. Rodenhuis, E. van der Wall, E. van der Schoot, 1993, The International journal of artificial organs.

Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP

S. Rodenhuis, J. Verweij, J. Schornagel, 1999, International journal of cancer.

A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.

S. Rodenhuis, H. Keizer, E. de Vries, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.

S. Rodenhuis, D. Richel, J. Schornagel, 1995, Cancer investigation.

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.

S. Rodenhuis, J. Baars, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

S. Rodenhuis, J. Baars, J. Schornagel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom

S. Sleijfer, J. Blay, S. Rodenhuis, 2010, European journal of cancer.

An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.

S. Rodenhuis, H. van Tinteren, J. Kerst, 2013, Urologic oncology.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

S. Rodenhuis, J. Schellens, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.

S. Rodenhuis, O. Dalesio, A. V. van Oosterom, 1992, Seminars in oncology.

Resistance ot cisplatin and analogues: mechanisms and potential clinical implications

S. Rodenhuis, A. Graeff, R. Slebos, 2004, Cancer Chemotherapy and Pharmacology.

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy

S. Rodenhuis, J. Beijnen, W. Moolenaar, 2000, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin

S. Rodenhuis, J. Beijnen, R. Maes, 1995, Cancer Chemotherapy and Pharmacology.

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-intensive chemotherapy for locally advanced breast cancer

S. Rodenhuis, J. Schrama, 1999, Current oncology reports.

Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study

S. Rodenhuis, W. Boogerd, W. W. Bokkel Huinink, 2004, Cancer Chemotherapy and Pharmacology.

0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer

S. Rodenhuis, L. V. Veer, S. Mook, 2009 .

Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.

J. Blay, S. Rodenhuis, M. van Glabbeke, 1999, Anti-cancer drugs.

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Schornagel, A. Westermann, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

S. Rodenhuis, S. Linn, J. Stouthard, 2017 .

Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF).

S. Rodenhuis, W. W. ten Bokkel Huinink, L. Vlasveld, 1990, The Netherlands journal of medicine.

Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.

S. Rodenhuis, S. Iacobelli, S. Gundersen, 1989, Cancer treatment reviews.

Individualized chemotherapy doses with granulocyte colony stimulating factor support have survival and toxicity benefits over marrow supported high dose chemotherapy

S. Rodenhuis, 2001 .

Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer.

S. Rodenhuis, J. Wanders, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

S. Rodenhuis, J. Schellens, H. Rosing, 2000, Cancer Chemotherapy and Pharmacology.

Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.

S. Rodenhuis, J. Schornagel, J. Sein, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.

S. Rodenhuis, W. W. ten Bokkel Huinink, A. Hiemstra, 1997, European journal of cancer.

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

S. Rodenhuis, A. Huitema, M. Tibben, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

REVIEW OF CARBOPLATIN-BASED HIGH-DOSE CHEMOTHERAPY COMBINATIONS IN THE AUTOTRANSPLANT SETTING

S. Rodenhuis, J. Baars, J. Schornagel, 1996 .

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

S. Rodenhuis, J. Verweij, J. Schellens, 1996, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1990, Journal of pharmaceutical and biomedical analysis.

Inefficacy of Plasma Exchange in Cold Agglutinin Hemolytic Anemia — A Case Study

S. Rodenhuis, Prakash Das, Annelies Maas, 1985, Vox sanguinis.

Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations

S. Rodenhuis, J. Wanders, J. Beijnen, 1992, The Annals of pharmacotherapy.

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

S. Rodenhuis, M. Muller, E. Wall, 1998, Journal of the National Cancer Institute.

Invasive aspergillosis complicated by subclavian artery occlusion and costal osteomyelitis after autologous bone marrow transplantation.

S. Rodenhuis, L. Vlasveld, J. Beynen, 1992, Thorax.

Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin.

S. Rodenhuis, H. Sluiter, H. Kauffman, 1984, Thorax.

Invasive pulmonary aspergillosis inanon-immunosuppressed patient: successful managementwithsystemic amphotericin andflucytosine andinhaled amphotericin

S. Rodenhuis, Henk Jsluiter, 1984 .

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer Chemotherapy and Pharmacology.

Growth factors in human ovarian cancer.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Cancer treatment reviews.

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of

J. Blay, S. Rodenhuis, M. van Glabbeke, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma?

S. Rodenhuis, T. Ockhuizen, V. Fidler, 1985, British journal of haematology.

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular markers of breast cancer metastasis

A. Hart, S. Rodenhuis, B. Weigelt, 2005 .

High-dose chemotherapy regimens for solid tumors.

S. Rodenhuis, E. van der Wall, J. Beijnen, 1995, Cancer treatment reviews.

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.

S. Rodenhuis, G. Snow, J. Verweij, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

Lodewyk F. A. Wessels, Lennart Mulder, S. Rodenhuis, 2009, Breast Cancer Research and Treatment.

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

M. J. van de Vijver, S. Rodenhuis, P. Kristel, 2006, British Journal of Cancer.

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness

S. Rodenhuis, L. Wessels, P. Nederlof, 2011, Breast Cancer Research.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

M. J. van de Vijver, S. Rodenhuis, M. Hauptmann, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

J. Blay, S. Rodenhuis, M. van Glabbeke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

O. S. Nielsen, J. Blay, S. Rodenhuis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2008, Pharmacogenetics and genomics.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2009, British journal of clinical pharmacology.

Absence of ras gene mutations in early gastric carcinomas.

S. Rodenhuis, P. Blok, G. Offerhaus, 1995, Gut.

Allele‐specific detection of K‐ras oncogene expression in human non‐small‐cell lung carcinomas

S. Rodenhuis, G. Habets, R. Slebos, 2007, International journal of cancer.

The molecular genetics of human lung cancer.

S. Rodenhuis, R. Slebos, R. Slebos, 1989, The European respiratory journal.

Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.

S. Rodenhuis, S. Wagenaar, R. Slebos, 1989, British Journal of Cancer.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

S. Rodenhuis, J. Wesseling, E. Lips, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

S. Rodenhuis, S. Linn, G. Sonke, 2015, Cureus.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

S. Rodenhuis, M. Hauptmann, L. Wessels, 2014, Breast Cancer Research.

Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization.

S. Rodenhuis, M. Hauptmann, L. Wessels, 2009 .

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

S. Rodenhuis, J. Schellens, J. Beijnen, 2000, Clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

S. Rodenhuis, J. Beijnen, E. van der Wall, 1996, British Journal of Cancer.

Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver

S. Rodenhuis, R. Slebos, W. Mooi, 1991, International journal of cancer.

Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.

S. Rodenhuis, W. Gerritsen, C. E. van der Schoot, 1995, Blood.

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.

S. Rodenhuis, M. Muller, S. Schagen, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

The Diagnosis of Tumors.

D. Gouma, G. Giaccone, S. Rodenhuis, 1946, California and western medicine.

Identifying subgroup markers in heterogeneous populations

Guillem Rigaill, S. Rodenhuis, L. Wessels, 2013, Nucleic acids research.

Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.

S. Rodenhuis, O. Dalesio, A. te Velde, 1996, Anticancer research.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

D. Berry, S. Rodenhuis, J. Bergh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

S. Rodenhuis, M. Nooij, E. D. de Vries, 2003, The New England journal of medicine.

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

S. Rodenhuis, P. Nederlof, J. Wesseling, 2013, British Journal of Cancer.

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer treatment reviews.

ras oncogene activation and the expression of ras-related genes in human lung cancer

S. Rodenhuis, R. Slebos, G. Salomons, 1993 .

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

S. Rodenhuis, R. Bernards, E. Cuppen, 2015, Breast Cancer Research.

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

M. J. van de Vijver, S. Rodenhuis, P. Nederlof, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

S. Rodenhuis, H. Rosing, J. Beijnen, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

S. Rodenhuis, E. Rutgers, J. Wesseling, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Annuska M. Glas, A. Glas, S. Rodenhuis, 2010, Breast Cancer Research and Treatment.

Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2004, Clinical Cancer Research.

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung

S. Rodenhuis, R. Hruban, F. Askin, 1993 .

Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation.

S. Rodenhuis, E. van der Wall, C. E. van der Schoot, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.

S. Rodenhuis, A. Huitema, M. Tibben, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

S. Rodenhuis, H. Rosing, J. Beijnen, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS

S. Rodenhuis, J. Beijnen, A. Huitema, 2000 .

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

J. Peterse, S. Rodenhuis, J. Baars, 1998, The Lancet.

Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Therapeutic drug monitoring.

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

S. Rodenhuis, H. Rosing, J. Beijnen, 2004, Journal of mass spectrometry : JMS.

Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

S. Rodenhuis, A. Huitema, M. Tibben, 1999, Therapeutic drug monitoring.

Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Anti-cancer drugs.

A search for new metabolites of N,N',N''-triethylenethiophosphoramide.

S. Rodenhuis, A. Heck, J. Beijnen, 1999, Cancer research.

Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.

S. Rodenhuis, J. Beijnen, J. W. Zwikker, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Therapeutic drug monitoring.

In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation.

S. Rodenhuis, C. Voermans, W. Gerritsen, 2001, Blood.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer

D. Berry, S. Rodenhuis, L. Esserman, 2012, Breast Cancer Research and Treatment.

Downstaging of an Advanced Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib

J. Peterse, S. Rodenhuis, R. van Hillegersberg, 2004, Digestive Surgery.

The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid

S. Rodenhuis, J. Beijnen, O. Tellingen, 2004, Cancer Chemotherapy and Pharmacology.

High dose chemotherapy in breast cancer reviewed

S. Rodenhuis, J. Baars, J. Schornagel, 1995 .

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

S. Rodenhuis, P. Nederlof, J. Wesseling, 2012, Breast Cancer Research and Treatment.

Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.

Kenneth G A Gilhuijs, Claudette E Loo, Marie-Jeanne Vrancken Peeters, 2008, AJR. American journal of roentgenology.

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

S. Rodenhuis, J. Wesseling, E. Lips, 2013, Breast Cancer Research and Treatment.

Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support

S. Rodenhuis, J. Baars, H. V. D. Lelie, 1995, Cancer.

Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer.

S. Rodenhuis, P. Sonneveld, A. Ho, 1990, Journal of the National Cancer Institute.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1989, European Journal of Cancer and Clinical Oncology.

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, S. Rodenhuis, M. van Glabbeke, 1999, European journal of cancer.

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma

S. Rodenhuis, H. Keizer, J. Schellens, 2001, European Journal of Clinical Pharmacology.

Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2005, Clinical pharmacokinetics.

Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer

S. Rodenhuis, J. Schrama, G. Gast, 2003, Bone Marrow Transplantation.

Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.

S. Rodenhuis, W. W. ten Bokkel Huinink, A. Westermann, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.

S. Rodenhuis, J. Baars, D. Richel, 1996, European journal of cancer.

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

S. Rodenhuis, H. Rosing, J. Beijnen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer

S. Rodenhuis, J. Beijnen, J. Schrama, 2001, Bone Marrow Transplantation.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

S. Rodenhuis, S. Linn, J. Wesseling, 2015, Breast Cancer Research and Treatment.

Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells.

S. Rodenhuis, J. Bertino, R. Narayanan, 1986, Cancer research.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Marie-Christine W. Gast, S. Rodenhuis, P. Span, 2008, BMC Cancer.

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The status of high-dose chemotherapy in breast cancer.

S. Rodenhuis, 2000, The oncologist.

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods.

S. Rodenhuis, L. J. Veer, A. Lambrechts, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Chapterr 4. Phasee II study of a multi-course high-dose chemotherapy regimen incorporatingg cyclophosphamide, thiotepa, and carboplatin in stagee IV breast cancer

S. Rodenhuis, J. Beijnen, J. Schrama, 2007 .

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

S. Rodenhuis, S. Linn, J. Wesseling, 2017, European journal of cancer.

Paclitaxel, Carboplatin, and Trastuzumab in a Neo‐adjuvant Regimen for HER2‐positive Breast Cancer

S. Rodenhuis, S. Linn, J. Wesseling, 2013, The breast journal.

A. C. Dubbelman, S. Rodenhuis, E. Rutgers, 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

M. J. van de Vijver, S. Rodenhuis, S. Linn, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes

S. Rodenhuis, E. Rutgers, J. Wesseling, 2017, PloS one.

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

S. Rodenhuis, L. Rigter, J. Wesseling, 2016, Breast Cancer Research.

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients

S. Rodenhuis, H. Boezen, M. Nooij, 2008, Bone Marrow Transplantation.

Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.

S. Rodenhuis, R. Dubbelman, R. Kröger, 1993, Thorax.

Early onset of oral aphthous ulcers with weekly docetaxel.

S. Rodenhuis, E. G Oumlker, 2005, The Netherlands journal of medicine.

Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy

S. Rodenhuis, E. Rutgers, J. Wesseling, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

S. Rodenhuis, E. Rutgers, J. Wesseling, 2013, Breast.

Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy

S. Rodenhuis, E. Rutgers, J. Wesseling, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy

S. Rodenhuis, E. Rutgers, P. Elkhuizen, 2012, Breast Cancer Research and Treatment.

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.

S. Rodenhuis, E. Rutgers, J. Wesseling, 2009, European journal of cancer.

Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence–based amplification for the detection of circulating breast cancer cells

S. Rodenhuis, L. J. Veer, S. Rodenhuis, 1999, Breast Cancer Research and Treatment.

Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.

S. Rodenhuis, O. Dalesio, H. van Tinteren, 1992, Pathologie-biologie.

Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

S. Rodenhuis, R. Slebos, A. de Graeff, 1988, Cancer chemotherapy and pharmacology.

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone

S. Rodenhuis, M. Gallee, B. Taal, 2004, Cancer Chemotherapy and Pharmacology.

A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc)

Gunnar B. Kristensen, S. Rodenhuis, C. Poole, 2010 .

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

S. Rodenhuis, E. Rutgers, S. Linn, 2010, Annals of Surgical Oncology.

Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer

S. Rodenhuis, M. Bontenbal, E. Vries, 2005, Breast Cancer Research and Treatment.

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer : Update of the Dutch randomized

S. Rodenhuis, M. Nooij, D. Richel, 2005 .

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

S. Rodenhuis, M. Nooij, E. Wall, 2005, Breast Cancer Research.

Intraperitoneal chemotherapy for malignant peritoneal mesothelioma.

S. Rodenhuis, M. Gallee, B. Taal, 1991, European journal of cancer.

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1997, Seminars in oncology.

Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study.

S. Rodenhuis, W. W. ten Bokkel Huinink, B. Taal, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease.

S. Rodenhuis, E. Rutgers, P. Elkhuizen, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

S. Rodenhuis, L. Rigter, J. Wesseling, 2016, Breast Cancer Research.

EAP in advanced gastric cancer.

S. Rodenhuis, W. W. ten Bokkel Huinink, B. Taal, 1990, Journal of Clinical Oncology.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer

S. Rodenhuis, E. Rutgers, J. Wesseling, 2017, Cancer Imaging.

Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules

A. C. Dubbelman, S. Rodenhuis, J. Beijnen, 1996 .

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

J. Peterse, S. Rodenhuis, J. Baars, 1996, British Journal of Cancer.

Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.

J. Peterse, S. Rodenhuis, D. Richel, 1993, Annals of Oncology.

Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.

S. Rodenhuis, J. Bertino, J. McGuire, 1987, Leukemia.

940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E)

S. Rodenhuis, J. Beijnen, J. Schornagel, 1995 .

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques

S. Rodenhuis, E. Rutgers, H. Oldenburg, 2011, Breast Cancer Research and Treatment.

Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.

S. Rodenhuis, M. Nooij, C. Seynaeve, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer studies in the Netherlands

S. Rodenhuis, O. Dalesio, E. Vries, 1996, The Lancet.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

J. Blay, S. Rodenhuis, G. Demetri, 2013 .

Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer

A. Witteveen, S. Rodenhuis, E. Rutgers, 2004 .

Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.

W. M. Smit, S. Rodenhuis, N. Aaronson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy in breast cancer. The Dutch trial

S. Rodenhuis, O. Dalesio, M. Nooij, 2001 .

High-Dose Chemotherapy for Breast Cancer

S. Rodenhuis, C. Mastenbroek, E. de Vries, 1997, Annals of Internal Medicine.

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.

S. Rodenhuis, O. Dalesio, C. Meijer, 1990, The New England journal of medicine.

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

M. Marton, S. Friend, M. J. van de Vijver, 2002 .

A gene-expression signature as a predictor of survival in breast cancer.

Van, M. Marton, S. Friend, 2002, The New England journal of medicine.

Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood.

S. Rodenhuis, J. Bos, L. Smets, 1986, Blood.

Interpretation of contrast enhanced MRI for early prediction of breast-cancer response to neoadjuvant chemotherapy: Initial results

Kenneth G. A. Gilhuijs, S. Rodenhuis, K. Gilhuijs, 2008 .

A gene-expression signature as a predictor of survival in breast cancer.

M. Marton, S. Friend, M. J. van de Vijver, 2002, The New England journal of medicine.

Detection of circulating breast tumor cells by differential expression of marker genes.

A. Hart, S. Rodenhuis, B. Weigelt, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel applications of growth factors in solid tumors

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1999 .

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

M. Marton, S. Friend, M. J. van de Vijver, 2002 .

Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer.

S. Rodenhuis, W. W. ten Bokkel Huinink, B. Taal, 1993, European journal of cancer.

Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer

S. Rodenhuis, W. Mooi, H. Elbers, 1995, International journal of cancer.

K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung

S. Rodenhuis, R. Hruban, F. Askin, 1993, Cancer.

Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

High-dose chemotherapy in breast cancer - interpretation of the randomized trials

S. Rodenhuis, 2001, Anti-cancer drugs.

Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers.

S. Rodenhuis, R. Slebos, N. van Zandwijk, 1988, European journal of cancer & clinical oncology.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

M. J. van de Vijver, J. Peterse, D. Atsma, 2007, The Lancet. Oncology.

Paclitaxel, Carboplatin, and Trastuzumab in a Neo‐adjuvant Regimen for HER2‐positive Breast Cancer

S. Rodenhuis, S. Linn, J. Wesseling, 2013, The breast journal.

Detection of circulating breast tumor cells by differential expression of marker genes.

A. Hart, S. Rodenhuis, B. Weigelt, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant therapy for breast cancer

S. Rodenhuis, E. Rutgers, 2006, The British journal of surgery.

Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.

W. M. Smit, S. Rodenhuis, N. Aaronson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.

S. Rodenhuis, D. Harnden, R. Slebos, 1989, British Journal of Cancer.

Absence of ras gene mutations in early gastric carcinomas.

S. Rodenhuis, P. Blok, M. Craanen, 1995, Gut.

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Baars, J. Schornagel, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies

S. Sleijfer, J. Blay, S. Rodenhuis, 2008 .